Your browser doesn't support javascript.
A case of pulmonary mucormycosis in a post COVID patient treated in a different scenario
Lung India ; 39(SUPPL 1):S140, 2022.
Article in English | EMBASE | ID: covidwho-1857660
ABSTRACT

Background:

Pulmonary Mucormycosis was rare pulmonary fungal disease ,which was difficult to diagnose early and lack effective treatment but during COVID-19 pandemic the testing modalities have become handy , usually it used to occur in immune compromised patients , present days post Covid pulmonary mucor has become common. Case Study A case of 60yrs old male patient , hypertensive, post Covid presented with cough associated with black coloured sputum, also with streaky haemoptysis and sob on exertion ,CT chest revealed left upper lobe thick walled cavity with reverse halo sign with lower septated cavity , with post covid lung fibrosis.

Discussion:

Pulmonary Mucormycosis may develop by inhalation of spores or by hematogenous or lymphatic spread, mostly seen in immune compromised patient, the sequelae include angioinvasion and direct tissue injury it may cause severe morbidity and mortality sputum and BAL cultures and radiological investigations are the crucial modalities for diagnosis sputum and BAL cytology may be inconclusive however early diagnosis will prevent the patient from life threatening complications and at times alternative drugs in unavoidable situations can prevent patient from life threatening complications.

Conclusion:

Different scenarios may be challenging.
Keywords
Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Screening study Topics: Long Covid Language: English Journal: Lung India Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Screening study Topics: Long Covid Language: English Journal: Lung India Year: 2022 Document Type: Article